Baylor Scott & White Research Institute Becomes First Site in The World to Enroll Patients in the NIH ACTIV-3 Clinical Trial

Team members from the investigational pharmacy help deliver some of the very first doses of an experimental monoclonal antibody to treat hospitalized COVID-19 patients as part of a landmark clinical trial.